Seraxis Announced Closing of $40M Series C Financing Round.

About Seraxis, Inc.

Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes. Our team of scientists have developed a novel cell and immune-evasion technologies that, together, reverse diabetes in animal models. We are currently working to advance this therapy to the clinic.